{
    "clinical_study": {
        "@rank": "144473", 
        "arm_group": {
            "arm_group_label": "intravitreal bevacizumab injection", 
            "arm_group_type": "Experimental", 
            "description": "intravitreal injection of bevacizumab 1.25 mg"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the efficacy of intravitreal bevacizumab injections for treatment of\n      proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after\n      previous full panretinal photocoagulation (PRP)."
        }, 
        "brief_title": "Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Vitreous Hemorrhage", 
            "Proliferative Diabetic Retinopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Retinopathy", 
                "Hemorrhage", 
                "Retinal Diseases", 
                "Vitreous Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators will carry out a prospective study  in patients with PDR and prior\n      complete laser treatment who presented with new dense VH. All eyes will be treated with\n      intravitreal injection of bevacizumab (1.25 mg). Complete ophthalmic examination and/or\n      ocular ultrasonography will be performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months\n      after first injection. Re-injection will be done in non-clearing and recurrent VH."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with diabetes mellitus\n\n          -  proliferative diabetic retinopathy\n\n          -  prior complete panretinal photocoagulation\n\n          -  presented with new dense vitreous hemorrhage\n\n        Exclusion Criteria:\n\n          -  one-eyed patient\n\n          -  previous intraocular surgery\n\n          -  severe lens opacity precluding fundus examination\n\n          -  advance glaucoma\n\n          -  history of thromboembolic events such as myocardial infarction and   cerebrovascular\n             accident\n\n          -  uncontrolled systemic hypertension, systolic blood pressure > 180 mmHg or diastolic\n             blood pressure > 110 mmHg\n\n          -  known coagulation abnormalities or current use of anticoagulant medications other\n             than aspirin\n\n          -  known allergies to any relevant drugs in this study\n\n          -  evidence of external ocular infection such as conjunctivitis and significant\n             blepharitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724385", 
            "org_study_id": "I55116"
        }, 
        "intervention": {
            "arm_group_label": "intravitreal bevacizumab injection", 
            "description": "intravitreal injection of bevacizumab", 
            "intervention_name": "intravitreal injection of bevacizumab", 
            "intervention_type": "Drug", 
            "other_name": "Avastin"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bevacizumab,", 
            "proliferative diabetic retinopathy,", 
            "vitreous hemorrhage,"
        ], 
        "lastchanged_date": "April 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Khon Kaen", 
                    "country": "Thailand", 
                    "zip": "40002"
                }, 
                "name": "Srinagarind Hospital, Khon Kaen University"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation", 
        "other_outcome": {
            "description": "Numbers of intravitreous bevacizumab injection in a 12-month period", 
            "measure": "Numbers of injection", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "overall_official": {
            "affiliation": "Department of Ophthalmology, Faculty of Medicine, Khon Kaen University", 
            "last_name": "Suthasinee Sinawat, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Thailand: Khon Kaen University Ethics Committee for Human Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The patients with PDR and prior complete laser treatment who presented with new dense VH. All eyes were treated with intravitreal bevacizumab injection. Complete ophthalmic examination and/or ocular ultrasonography were performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection.", 
            "measure": "The percentage of eyes that vitreous hemorrhage  has been completely resolved", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724385"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Khon Kaen University", 
            "investigator_full_name": "Yosanan  Yospaiboon", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The best corrected visual acuity (BCVA) was performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection.", 
            "measure": "The change in best corrected visual acuity (BCVA) from baseline", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Khon Kaen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Khon Kaen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}